Targeted agents to improve MS prognosis were also frequently reported such as tyrosine kinase inhibitors (TKI), DNA methyltransferase inhibitors, and CD33 monoclonal antibodies (34, 35). The gene discussed is CD33; the disease is myeloid sarcoma.